All material subject to strictly enforced copyright laws. © 2021 Euromoney Institutional Investor PLC group
EquityEquity - Follow-ons and Rights issues

Autolus prices US raise as biotech equity wave continues

biopharma_stocks_adobe_575x375.jpg

UK biotech firms are continuing to reap the benefits from US listings. On Tuesday Autolus Therapeutics, an early stage biopharma firm backed by Syncona Investments, became the latest UK Biotech firm to raise capital on the US Nasdaq in a $100m transaction. The deal shows the continued advantages for early stage European biotech firms in having a US listing.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree